Personalized therapy of menopausal syndrome in combination with perimenopausal melatonin deficiency syndrome

Mamontova Alexandra

Menopausal syndrome (MS) is the leading manifestation of pathological menopause. Along with the deficiency of sex steroids in MS, there is a change in the synthesis of the pineal gland hormone melatonin (MT), which leads to the formation of perimenopausal melatonin deficiency syndrome (PMDS). We have developed an algorithm for stratification of women in the menopausal transition and postmenopausal women with MS in combination with PMDS for the selection of differentiated therapy. The purpose of this study was to evaluate the effectiveness of the developed algorithm. The study included 163 women: groups 1, 2, 3, and 4 included patients with MS and sleep disturbance, the control group 5 included women with physiological postmenopause. Patients’ quality of life (QOL) was assessed according to a special WHQ questionnaire after collecting their anamnesis, assessing anthropometric data, determining the severity of MS and the hormonal profile. Statistical data processing was carried out using the SPSSv13.0 program. At the initial point of the study before the therapy, the χ2 criterion was applied and in dynamics - the Wilcoxon test. Based on the study, the high clinical efficacy of the developed algorithm for stratification of women for the selection of differentiated therapy in the menopausal transition and postmenopausal patients with CS in combination with PMDS has been proved.

Keywords:climacteric syndrome, women, melatonin, phytoestrogens, menopausal hormone therapy, quality of life.